Potential buyers need to be very aware of the financial situation of this company and a number of other salient realities which are conspicuously absent in their recent campaign to boost the share price. Contrary to what one commentator on this site said, this is not a company that Lynch would consider for a second. He did not achieve his considerable success by ignoring the fundamentals and buying on hype. For example, their financials paint a very disturbing picture. The company has been losing money at an accelerating rate since going public. The original investors have pulled out much of the cash the company needs to continue operations and to promote its rather limited product line. The recent SEC filing shows that at the present rate of spend the company has only a two or three months of cash left. Their products are not unique nor are they best in class by any measure. This is reflected in the low sales volume they have experienced in the GNC shops. Adding a few other retailers will not remedy this problem, and they do not have the resources to mount a major marketing campaign. Another caution flag is the hiring of Redchip to pump the stock. They are essentially paying this once highly reputable firm $15,000 per month from their dwindling kitty to give them a "Buy" rating. This may have worked a few years ago, but today most investors know that Redchip sells these favorable ratings. The single independent rating at Hotstocks is a strong sell. Management is another area of concern. The investors installed a new CEO from the handgun industry who has no experience or credentials in the dietary supplement industry, an extremely competitive and tough marketing and product environment. Penny stocks are not as regulated as shares selling on the major exchanges. The buyer is expected to do his own due diligence and to understand that companies on this exchange can be highly risky. Most do not succeed. It is difficult to find much reason to believe that Chromadex will be an exception.